Armbrecht Jackson LLP is Principal External Counsel on RLS’s $230+ million Acquisition by Telix

As its Principal External Counsel, Armbrecht Jackson LLP represented RLS (USA), Inc., one of the largest chains of nuclear pharmacies in the U.S.,  in negotiating and closing RLS’s acquisition by Telix Pharmaceuticals Limited. Telix is a biopharmaceutical company that is listed on the Australian Securities Exchange.

The acquisition closed on January 27, 2025, with Telix acquiring 100% ownership of RLS. The purchase price included upfront cash of approximately US$230 million, prior to adjustments for deferred cash consideration, working capital, transaction expenses, debt and debt equivalents, plus contingent cash of up to US$20 million, which is conditional upon post-closing  milestones based on RLS’ financial and operational performance in the next four quarters.

Read the transaction press release

The Armbrecht Jackson team was led by partners Tom Oldweiler and David Anthony.